Gland Pharma up 3.0% on USFDA nod for Depo‑Medrol rival in USD 214m market

In a press release dated November 03, 2026, Gland Pharma Limited said it has received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Methylprednisolone Acetate Injectable Suspension USP.

The filing on page 2 specifies that the approval covers:

• 40 mg/mL and 80 mg/mL Single-Dose Vials
• 200 mg/5 mL (40 mg/mL) Multiple-Dose Vials
• 400 mg/10 mL (40 mg/mL) Multiple-Dose Vials
• 400 mg/5 mL (80 mg/mL) Multiple-Dose Vials

The product is described as "bioequivalent and therapeutically equivalent" to the reference listed drug Depo‑Medrol Injectable Suspension, 40 mg/mL and 80 mg/mL, of Pfizer Inc.

According to the press release, Methylprednisolone Acetate Injectable Suspension is indicated for a wide range of conditions, including:

• Allergic states
• Dermatologic diseases
• Endocrine disorders
• Gastrointestinal diseases
• Hematologic disorders
• Neoplastic diseases
• Nervous system and ophthalmic diseases
• Renal and respiratory diseases
• Rheumatic disorders and other miscellaneous indications

This breadth of indications underpins why the market sees the product as commercially relevant rather than a niche launch.

The key driver for the stock reaction was not just the fact of another approval, but the size and profile of the reference market and the positioning versus Pfizer’s Depo‑Medrol.

The press release cites IQVIA data, stating that "the Methylprednisolone injection had US sales of approximately USD 214 million for the twelve months ending August 2026." That gives investors a concrete sense of the opportunity Gland is targeting, even though the company has not shared its own revenue expectations.

Market commentary following the announcement highlighted three elements:

1. Targeting a sizeable US market: With US sales of approximately USD 214 million for the twelve months ending August 2026, the molecule sits in a higher-value injectable segment compared with many smaller generic launches.
2. Direct competition with a branded incumbent: The product’s bioequivalence and therapeutic equivalence to Pfizer’s Depo‑Medrol positions Gland to participate in a well‑established corticosteroid franchise once it is commercialised.
3. Reinforcement of the core injectable strategy: Gland describes itself in the filing as a "generic injectable & ophthalmic‑focused pharmaceutical company" with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. The approval fits squarely into that strategy, which the market tends to reward when backed by tangible addressable-market numbers.

Given that the stock was modestly lower before the filing and then moved higher in the hours after, the USFDA approval appears to be the main catalyst for the 3.0% gain on the day.

While the market is extrapolating from the USD 214 million reference market, the filing itself is notably silent on several points that would matter for a fuller financial assessment:

• No revenue or profit guidance: The press release does not provide any estimate of potential sales, launch timelines, or margin impact from Methylprednisolone Acetate Injectable Suspension.
• No pricing or competitive landscape detail: There is no information on how many generic players are already in the US market for this molecule, or how aggressively Gland intends to price its product.
• No capex or investment disclosure: The filing does not mention any incremental capital expenditure or manufacturing changes tied specifically to this product.

Investors therefore only know that Gland now has the regulatory clearance to sell a product in a US market that IQVIA pegs at approximately USD 214 million in annual sales. How much of that pool Gland can capture, and at what profitability, is not addressed in the document.

The press release also reiterates Gland’s broader positioning. Established in 1978 in Hyderabad, the company notes that it has grown from a contract manufacturer of small‑volume liquid parenteral products to "one of the largest injectable‑focused companies" with a global footprint across 60 countries.

It operates primarily under a business‑to‑business (B2B) model and highlights an "excellent track record" in developing, manufacturing and marketing sterile injectables. Its portfolio spans vials, ampoules, pre‑filled syringes, lyophilized vials, dry powders, infusions, oncology and ophthalmic solutions, and it notes that it pioneered Heparin technology in India.

Against that backdrop, the Methylprednisolone Acetate approval is being interpreted as another data point that Gland is continuing to add differentiated, higher‑value injectable products for the US market. That narrative, combined with the explicit USD 214 million market size disclosed in the filing, helps explain why the stock reacted positively even in the absence of immediate financial numbers.

With the shares ending the session at Rs 3,160, the 3.0% rise reflects the market’s attempt to price in incremental earnings potential from a new US generic that:

• Targets a clearly quantified US market of approximately USD 214 million in annual sales
• Is bioequivalent and therapeutically equivalent to Pfizer’s Depo‑Medrol
• Fits neatly into Gland’s established injectable‑focused, B2B‑heavy business model

At the same time, the filing does not break out any revenue, profit or margin contribution from this product, nor does it discuss launch timing. The move therefore rests on expectations rather than hard financial data for now, and future quarters will determine how much of the USD 214 million opportunity Gland can actually convert into earnings.